CD274 and neoplasm: Currently, the main biomarkers for the selection of patient cohorts include PD‐L1 overexpression, microsatellite instability (MSI), and high tumor mutational burden (TMB).8, 9, 10 Among them, detection of PD‐L1 expression is the most common and convenient method.